High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

• Principais autores: Andrew Hill (Autor), Giten Khwairakpam (Autor), James Wang (Autor), Sergey Golovin (Autor), Julia Dragunova (Autor), Rachel Smith (Autor), Vicky Houghton-Price (Autor), Roxanna Korologou-Linden (Autor), Sanjay Nath (Autor), Anna Savage (Autor), Greg Jefferys (Autor)
• Formato: Livro
• Publicado em: Elsevier, 2017-10-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China,...